financetom
Business
financetom
/
Business
/
US STOCKS-Dow, S&P 500 drop ahead of earnings; investors cautious after 6 weekly gains
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US STOCKS-Dow, S&P 500 drop ahead of earnings; investors cautious after 6 weekly gains
Oct 22, 2024 12:45 PM

*

Boeing ( BA ) gains after offering new wage deal

*

Humana, Cigna ( CI ) fall after report companies resumed merger

talks

*

114 S&P 500 companies to report results this week

*

Nvidia ( NVDA ) briefly touches record high

*

Indexes: Dow down 0.85%, S&P 500 down 0.29%, Nasdaq flat

(Updated at 2:15pm ET/6:15pm GMT)

By Lisa Pauline Mattackal, Purvi Agarwal and Carolina Mandl

Oct 21 (Reuters) -

The Dow Jones Industrial Average and S&P 500 fell on Monday,

as investors awaited earnings from major companies to gauge

whether equities will sustain the recent rally that has brought

six straight weekly gains.

"It's not at all unusual for the market to want to take

a little bit of a breather after six weeks of continually record

highs," said Carol Schleif, chief investment officer at BMO

Family Office.

At 02:15 p.m. the Dow Jones Industrial Average fell

368.73 points, or 0.85%, to 42,907.18, the S&P 500 lost

17.04 points, or 0.29%, to 5,847.63 and the Nasdaq Composite

gained 11.04 points, or 0.06%, to 18,500.59.

A jump in Treasury yields added pressure, with the yield

on the benchmark 10-year bond rising as high as 4.17%, a 12-week

high.

"Rates are going up because there is a thought that

maybe the Federal Reserve won't cut two times before the year's

over. You see economic data coming in a little bit stronger than

anticipated," said David Laut, chief investment officer at

Abound Financial.

Most rate-sensitive megacap technology stocks slipped,

with Tesla down 1.3%, and Microsoft ( MSFT ) and Meta

Platforms ( META ) both losing 0.4%.

After a fairly upbeat start to earnings season, the

focus is on the 114 S&P 500 companies scheduled to report this

week. These include Tesla, Coca-Cola and Texas

Instruments ( TXN ).

Of companies that have reported so far, 83.1% beat

earnings estimates, according to data compiled by LSEG on

Friday.

Some traders were likely booking profits, Tim Ghriskey,

senior portfolio strategist with Ingalls & Snyder, said.

On Friday, the Dow and the S&P 500 both closed at record

highs as all three major indexes closed out a sixth consecutive

week of gains, their longest winning streak this year.

Monday's declines were broad, with almost all 11 major

S&P 500 sectors in the red, except for Information Technology

.

The rate-sensitive Real Estate sector dropped

1.77% as yields rose, while the technology sector was lifted by

a 3% jump in chip heavyweight Nvidia ( NVDA ), which briefly

touched a fresh record high.

The economically sensitive small-cap Russell 2000

dropped 1.4%.

Investors also looked ahead to the upcoming U.S.

presidential election, with polls showing the chances improving

for former President Donald Trump, the Republican candidate.

"As the election date approaches, even small changes in

tight polls could drive seemingly erratic swings in market

sentiment," Danske Bank analysts said.

Meanwhile, Boeing ( BA ) jumped 3.2% after news that

workers could vote on a new deal to end a costly five-week

strike.

Spirit Airlines ( SAVE ) skyrocketed 51.7% after the company

reached an agreement to extend a debt refinancing deadline by

two months.

Humana slipped 1.82% after a report said Cigna ( CI )

had resumed merger talks with the health insurer. Cigna's ( CI )

shares lost 4.32%.

Home sales, flash PMI and durable goods reports are on

the data docket through the week, as is the Fed's Beige Book.

Declining issues outnumbered advancers by a 3.83-to-1

ratio on the NYSE. There were 226 new highs and 39 new lows on

the NYSE.

The S&P 500 posted 41 new 52-week highs and 2 new lows

while the Nasdaq Composite recorded 82 new highs and 41 new

lows.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Rezolve Ai Reaffirms Recurring Sales Outlook Over $200 Million; Shares Extend Gains Premarket
Update: Rezolve Ai Reaffirms Recurring Sales Outlook Over $200 Million; Shares Extend Gains Premarket
Mar 10, 2026
04:51 AM EST, 12/17/2025 (MT Newswires) -- (Updates with the stock move in the headline and the third paragraph.) Rezolve Ai ( RZLV ) said Tuesday it expects December revenue to exceed $17 million and reaffirmed its full-year 2026 recurring revenue outlook of $500 million or more. One analyst surveyed by FactSet expects $264 million. The company's estimates are based...
Constellation Energy Gets Operating License Renewals for Two Illinois Facilities
Constellation Energy Gets Operating License Renewals for Two Illinois Facilities
Mar 10, 2026
03:06 PM EST, 12/16/2025 (MT Newswires) -- Constellation Energy ( CEG ) said Tuesday the initial 20-year license renewal for its Clinton Clean Energy Center and 20-year subsequent license renewal for its Dresden Clean Energy Center, both in Illinois, have been approved by the Nuclear Regulatory Commission. The approvals allow Clinton to operate through 2047 and the Dresden reactors to...
TotalEnergies Sells 50% Stake in Greek Renewables Portfolio for $595.4 Million
TotalEnergies Sells 50% Stake in Greek Renewables Portfolio for $595.4 Million
Mar 10, 2026
04:46 AM EST, 12/17/2025 (MT Newswires) -- TotalEnergies SE ( TTE ) said Wednesday that it has completed the sale of a 50% stake in its 424 MW wind and solar portfolio in Greece to Asterion Industrial Partners for 508 million euros ($595.4 million), or about 1.2 million euros per MW. The company said the sale fits its renewable strategy...
Sanofi Says Efdoralprin Alfa Gets Orphan Drug Designation in EU
Sanofi Says Efdoralprin Alfa Gets Orphan Drug Designation in EU
Mar 10, 2026
04:54 AM EST, 12/17/2025 (MT Newswires) -- Sanofi ( SNY ) said Wednesday its investigational efdoralprin alfa fusion protein has received the European Medicines Agency's orphan drug designation to potentially treat alpha-1 antitrypsin deficiency-related emphysema, a rare respiratory condition. The decision was based on efdoralprin alfa meeting all primary and secondary endpoints in a global phase 2 trial. Efdoralprin alfa...
Copyright 2023-2026 - www.financetom.com All Rights Reserved